IQ Solutions

Recent papers from IQ Solutions

1. Time trends of human papillomavirus-attributable head and neck cancers: the BROADEN studyJNCI Journal of the National Cancer Institute · 2026
2. Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in South Korea – a population-based retrospective database studyBMC Public Health · 2026
3. Medical Unmet Needs in Uncontrolled Asthma Despite GINA Step 4/5 Treatment in PolandJournal of Asthma and Allergy · 2026
4. Real-world treatment patterns, healthcare resource utilization, and costs associated with high-risk endometrial cancer in England: a retrospective cohort studyJournal of Medical Economics · 2026
5. Culturally Adapted Floor-to-Stand Exercises for COPD: A Quasi-Experimental StudyThoracic research and practice · 2026
6. Introduction to Concepts in Artificial Intelligence and Machine Learning for Pharmacoepidemiologists: Large Language ModelsPharmacoepidemiology and Drug Safety · 2026
7. Dupilumab exposure and herpesvirus infection risk in atopic dermatitis: A claims‐based cohort studyJournal of the European Academy of Dermatology and Venereology · 2026
8. Preferences of people living with HIV for treatment regimen attributes: a qualitative interview studyFrontiers in Public Health · 2026
9. Real-world outcomes of lenvatinib versus sorafenib as the second-line therapy after atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: a large-scale multicenter study in KoreaHepatology International · 2026
10. Cost-effectiveness analysis of elranatamab versus physician’s choice of treatment (non–BCMA-directed regimens) in patients with triple class exposed multiple myeloma in JapanJournal of Medical Economics · 2026
11. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular OutcomesJournal of the American College of Cardiology · 2024
12. Real-world effectiveness of early nirmatrelvir/ritonavir initiation after COVID-19 diagnosis in outpatient setting against severe illness, hospitalization, death, and long COVID in N3CBMC Infectious Diseases · 2026
13. Whooping cough hospitalisations among patients with chronic conditions: a retrospective analysis of incidence and costs, France, 2008 to 2020Eurosurveillance · 2026
14. Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational StudyThe Journal of Rheumatology · 2026
15. Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the Psabiond Observational StudyThe Journal of Rheumatology · 2026
16. Development of the Physical Distancing Scale for COVID-19 Avoidance (PDS-C19©) in immunocompromised and non-immunocompromised individuals and its validation in the EAGLE StudyJournal of Patient-Reported Outcomes · 2026
17. Dimensions of implementation facilitation (IF): development of a tool for designing, documenting and reporting on IF strategies in healthcare settingsImplementation Science Communications · 2026
18. Myasthenia Gravis ( MG ) Resource Utilization, Epidemiology, Survival, and Treatment Patterns ( MG ‐ REST ): Estimating the Clinical and Economic Burden in Ontario, CanadaEuropean Journal of Neurology · 2026
19. Real-world treatments and outcomes in metastatic and recurrent esophageal squamous cell carcinoma in Japan: a retrospective analysis using the Millennial Medical Record databaseEsophagus · 2026
20. Perspectives on the definition of ‘evidence’: a qualitative interview study among interest-holdersBMJ evidence-based medicine · 2026